# US 2003/0068327 A1 · Compositions and methods for the diagnosis and threatment of herpes simplex virus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0068327 A1
- Document ID: US20030068327A1
- Status: Published application
- Kind: A1
- Application number: 10/121,988
- Filed: 2002-04-11
- Published: 2003-04-10
- Earliest claimed: 2000-06-29
- Assignees: Corixa Corporation
- Inventors: Nancy Ann Hosken; Patrick McGowan; Paul R. Sleath; Sally P. Mossman; Lawrence S. Evans; Ryan M. Swanson; Patricia D. McNeill
- Web page: https://patentgrep.com/patent/US20030068327A1

## CPC

- C07K 14/005: from viruses
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/53: {DNA (RNA) vaccination}
- C07K 2319/00: Fusion polypeptide
- C12N 2710/16622: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- G01N 2333/035: Herpes simplex virus I or II
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Compounds and methods for the diagnosis and treatment of HSV infection are provided. The compounds comprise polypeptides that contain at least one antigenic portion of an HSV polypeptide and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits are also provided comprising such polypeptides and/or DNA sequences and a suitable detection reagent for the detection of HSV infection in patients and in biological samples.

## Claims

### Claim 1

An isolated polypeptide comprising at least an immunogenic portion of an HSV antigen, wherein said antigen comprises an amino acid sequence set forth in any one of SEQ ID NO: 2, 3, 5, 6, 7, 10-12, 14-15, 17-18, 20-23, 25-33, 39-47, 50-51, 54-64, 74-75, 90-97, 120-121, 122-140, 142-143, 153-178, and 181.

### Claim 2 (depends on 1)

An isolated polynucleotide encoding a polypeptide of claim 1.

### Claim 3 (depends on 2)

An isolated polynucleotide of claim 2, wherein said polynucleotide comprises a sequence set forth in any one of SEQ ID NO: 1, 4, 8-9, 13, 16, 19 24, 35-38, 48-49, 52-53, 65-73, 76-89, 98-117, 118-119, 141, 144-152, 179-180 and 182-183.

### Claim 4

An isolated polypeptide comprising at least an immunogenic portion of a HSV UL46 antigen, wherein said antigen comprises an amino acid sequence set forth in SEQ ID NO: 15, and wherein said immunogenic portion is selected from the group consisting of SEQ ID NO: 27-33 and 59-62.

### Claim 5

An isolated polypeptide comprising at least an immunogenic portion of a HSV UL15 antigen, wherein said antigen comprises an amino acid sequence set forth in SEQ ID NO: 26, and wherein said immunogenic portion is selected from the group consisting of SEQ ID NO: 56-57.

### Claim 6

An isolated polypeptide comprising at least an immunogenic portion of a HSV US3 antigen, wherein said antigen comprises an amino acid sequence set forth in SEQ ID NO: 12, and wherein said immunogenic portion comprises SEQ ID NO: 63.

### Claim 7

An isolated polypeptide comprising at least an immunogenic portion of a HSV US8A antigen, wherein said antigen comprises an amino acid sequence set forth in SEQ ID NO: 7, and wherein said immunogenic portion comprises SEQ ID NO: 64.

### Claim 8

An isolated polypeptide comprising at least an immunogenic portion of a HSV2 UL39 antigen, wherein said antigen comprises an amino acid sequence set forth in SEQ ID NO:3, and wherein said immunogenic portion is selected from the group consisting of SEQ ID NOs:74-75.

### Claim 9

An isolated polypeptide comprising at least an immunogenic portion of a HSV2 ICP0 antigen, wherein said antigen comprises an amino acid sequence set forth in SEQ ID NOs:47, and wherein said immunogenic portion is selected from the group consisting of SEQ ID NO:46.

### Claim 10 (depends on 1)

A fusion protein comprising a polypeptide according to claim 1 and a fusion partner.

### Claim 11 (depends on 10)

A fusion protein according to claim 10, wherein the fusion partner comprises an expression enhancer that increases expression of the fusion protein in a host cell transfected with a polynucleotide encoding the fusion protein.

### Claim 12 (depends on 1, 10)

A fusion protein according to claim 10, wherein the fusion partner comprises a T helper epitope that is not present within the polypeptide of claim 1.

### Claim 13 (depends on 10)

A fusion protein according to claim 10, wherein the fusion partner comprises an affinity tag.

### Claim 14 (depends on 10)

An isolated polynucleotide encoding a fusion protein according to claim 10.

### Claim 15 (depends on 1)

An isolated monoclonal or polyclonal antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 1.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising a polypeptide according to claim 1 or a polynucleotide encoding said polypeptide, and a physiologically acceptable carrier.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising a polypeptide according to claim 1, or a polynucleotide encoding said polypeptide, and an immunostimulant.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the immunostimulant is selected from the group consisting of a monophosphoryl lipid A, aminoalkyl glucosaminide phosphate, saponin, or a combination thereof.

### Claim 19 (depends on 16, 17, 18)

A method for stimulating an immune response in a patient, comprising administering to a patient a pharmaceutical composition according to any one of claims 16-18.

### Claim 20 (depends on 1)

A method for detecting HSV infection in a patient, comprising:
(a) obtaining a biological sample from the patient;
(b) contacting the sample with a polypeptide according to claim 1; and
(c) detecting the presence of antibodies that bind to the polypeptide.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the biological sample is selected from the group consisting of whole blood, serum, plasma, saliva, cerebrospinal fluid and urine.

### Claim 22 (depends on 1)

A method for detecting HSV infection in a biological sample, comprising:
(a) contacting the biological sample with a binding agent which is capable of binding to a polypeptide according to claim 1; and
(b) detecting in the sample a polypeptide that binds to the binding agent, thereby detecting HSV infection in the biological sample.

### Claim 23 (depends on 22)

The method of claim 22, wherein the binding agent is a monoclonal antibody.

### Claim 24 (depends on 22)

The method of claim 22, wherein the binding agent is a polyclonal antibody.

### Claim 25 (depends on 22)

The method of claim 22 wherein the biological sample is selected from the group consisting of whole blood, sputum, serum, plasma, saliva, cerebrospinal fluid and urine.

### Claim 26 (depends on 1, 10, 15)

A diagnostic kit comprising a component selected from the group consisting of:
(a) a polypeptide according to claim 1;
(b) a fusion protein according to claim 10;
(c) at least one antibody, or antigen-binding fragment thereof, according to claim 15; and
(d) a detection reagent.

### Claim 27 (depends on 26)

The kit according to claim 26, wherein the polypeptide is immobilized on a solid support.

### Claim 28 (depends on 26)

The kit according to claim 26, wherein the detection reagent comprises a reporter group conjugated to a binding agent.

### Claim 29 (depends on 28)

The kit of claim 28, wherein the binding agent is selected from the group consisting of anti-immunoglobulins, Protein G, Protein A and lectins.

### Claim 30 (depends on 28)

The kit of claim 28, wherein the reporter group is selected from the group consisting of radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.
